8-KEarnings & ResultsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Oct 28, 2004)

Filed October 28, 2004For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on October 27, 2004, to announce its financial results for the quarter ended September 30, 2004. The key information for investors is contained within the accompanying press release, filed as Exhibit 99(a). This filing serves as a notification of the release of these results. While the 8-K itself does not detail the specific financial figures, it directs investors to the press release for the comprehensive quarterly performance. This is a standard procedure for publicly traded companies to disseminate important financial updates in a timely manner. Investors should refer to the referenced press release for details on revenue, expenses, net income, and any other relevant operational and financial condition metrics for the period.

Key Highlights

  • 1Regeneron Pharmaceuticals (REGN) announced its financial results for the quarter ended September 30, 2004.
  • 2The financial results were disclosed via a press release filed as Exhibit 99(a) to the 8-K.
  • 3The 8-K filing was made on October 27, 2004, with the event date of the announcement being October 26, 2004.
  • 4This filing is primarily a notification of the release of quarterly financial information.
  • 5Investors are directed to the press release for specific financial data and operational highlights.
  • 6The information in this 8-K is not deemed 'filed' for the purposes of securities laws, except where specifically incorporated by reference.

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly announce Regeneron Pharmaceuticals, Inc.'s financial results for the quarter ended September 30, 2004, as required by regulatory guidelines.

The detailed financial results, including revenue, expenses, and net income, are available in the press release filed as Exhibit 99(a) to this 8-K filing.

No, this specific 8-K filing does not contain the detailed financial numbers. It serves as a notification and directs investors to the accompanying press release (Exhibit 99(a)) for the full financial disclosure.

The statement indicates that the content of this 8-K, specifically the financial information announced, is not automatically considered part of Regeneron's official filings with the SEC for liability purposes under securities laws, unless the company explicitly chooses to incorporate it into future filings.